ID   RET_HUMAN               Reviewed;        1114 AA.
AC   P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 3.
DT   10-MAY-2017, entry version 227.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret;
DE            EC=2.7.10.1;
DE   AltName: Full=Cadherin family member 12;
DE   AltName: Full=Proto-oncogene c-Ret;
DE   Contains:
DE     RecName: Full=Soluble RET kinase fragment;
DE   Contains:
DE     RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment;
DE   Flags: Precursor;
GN   Name=RET; Synonyms=CDHF12, CDHR16, PTC, RET51;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   CYS-982.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2).
RX   PubMed=2660074;
RA   Takahashi M.;
RT   "Isolation of ret proto-oncogene cDNA with an amino-terminal signal
RT   sequence.";
RL   Oncogene 4:805-806(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1).
RX   PubMed=3078962;
RA   Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.;
RT   "Cloning and expression of the ret proto-oncogene encoding a tyrosine
RT   kinase with two potential transmembrane domains.";
RL   Oncogene 3:571-578(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH TRIM27.
RX   PubMed=3037315; DOI=10.1128/MCB.7.4.1378;
RA   Takahashi M., Cooper G.M.;
RT   "ret transforming gene encodes a fusion protein homologous to tyrosine
RT   kinases.";
RL   Mol. Cell. Biol. 7:1378-1385(1987).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH GOLGA5.
RC   TISSUE=Fibroblast;
RX   PubMed=2734021;
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RT   "Activation of the ret-II oncogene without a sequence encoding a
RT   transmembrane domain and transforming activity of two ret-II oncogene
RT   products differing in carboxy-termini due to alternative splicing.";
RL   Oncogene 4:789-794(1989).
RN   [8]
RP   ERRATUM.
RA   Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.;
RL   Oncogene 4:1415-1415(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL
RP   TRANSLOCATION WITH CCDC6.
RC   TISSUE=Thyroid papillary carcinoma;
RX   PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3;
RA   Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R.,
RA   Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.;
RT   "PTC is a novel rearranged form of the ret proto-oncogene and is
RT   frequently detected in vivo in human thyroid papillary carcinomas.";
RL   Cell 60:557-563(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL
RP   TRANSLOCATION WITH PCM1.
RX   PubMed=10980597; DOI=10.1038/sj.onc.1203772;
RA   Corvi R., Berger N., Balczon R., Romeo G.;
RT   "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.";
RL   Oncogene 19:4236-4242(2000).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24.
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused
RT   to the RET receptor tyrosine kinase in childhood papillary thyroid
RT   carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [12]
RP   PHOSPHORYLATION AT TYR-1015 AND TYR-1062.
RX   PubMed=11061555; DOI=10.1210/jcem.85.10.6882;
RA   Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G.,
RA   Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.;
RT   "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret
RT   and ret-derived oncoproteins.";
RL   J. Clin. Endocrinol. Metab. 85:3898-3907(2000).
RN   [13]
RP   PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981;
RP   TYR-1015; TYR-1062; TYR-1090 AND TYR-1096.
RX   PubMed=14711813; DOI=10.1074/jbc.M312600200;
RA   Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R.,
RA   Kato M., Suzuki H., Takahashi M., Nakashima I.;
RT   "Identification of RET autophosphorylation sites by mass
RT   spectrometry.";
RL   J. Biol. Chem. 279:14213-14224(2004).
RN   [14]
RP   CHROMOSOMAL TRANSLOCATION WITH TRIM27.
RX   PubMed=12787916; DOI=10.1016/S0027-5107(03)00056-3;
RA   Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A.,
RA   Lushnikov E., Roumiantsev P., Matsumoto N., Nakashima M.,
RA   Meirmanov S., Ohtsuru A., Namba H., Tsyb A., Yamashita S.;
RT   "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary
RT   thyroid carcinoma from externally irradiated patient.";
RL   Mutat. Res. 527:81-90(2003).
RN   [15]
RP   PHOSPHORYLATION AT TYR-905; TYR-1015 AND TYR-1062, AND
RP   DEPHOSPHORYLATION AT TYR-905; TYR-1015 AND TYR-1062 BY PTPRJ.
RX   PubMed=16778204; DOI=10.1158/0008-5472.CAN-06-0228;
RA   Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M.,
RA   Carlomagno F., Santoro M., Fusco A.;
RT   "The receptor-type protein tyrosine phosphatase J antagonizes the
RT   biochemical and biological effects of RET-derived oncoproteins.";
RL   Cancer Res. 66:6280-6287(2006).
RN   [16]
RP   ENZYME REGULATION.
RX   PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104;
RA   Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L.,
RA   Lackey K.;
RT   "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as
RT   potent RET kinase inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:5886-5893(2007).
RN   [17]
RP   ENZYME REGULATION BY SORAFENIB.
RX   PubMed=17664273; DOI=10.1074/jbc.M703461200;
RA   Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C.,
RA   Magee A.I., Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.;
RT   "Sorafenib functions to potently suppress RET tyrosine kinase activity
RT   by direct enzymatic inhibition and promoting RET lysosomal degradation
RT   independent of proteasomal targeting.";
RL   J. Biol. Chem. 282:29230-29240(2007).
RN   [18]
RP   ENZYME REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES.
RX   PubMed=19053769; DOI=10.1021/jm8007823;
RA   Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L.,
RA   Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.;
RT   "Synthesis, modeling, and RET protein kinase inhibitory activity of 3-
RT   and 4-substituted beta-carbolin-1-ones.";
RL   J. Med. Chem. 51:7777-7787(2008).
RN   [19]
RP   INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758.
RX   PubMed=18753381; DOI=10.1523/JNEUROSCI.2738-08.2008;
RA   Tsui C.C., Pierchala B.A.;
RT   "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the
RT   regulation of ret signal transduction.";
RL   J. Neurosci. 28:8789-8800(2008).
RN   [20]
RP   INTERACTION WITH AIP.
RX   PubMed=19366855; DOI=10.1210/jc.2008-1980;
RA   Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R.,
RA   Morra I., Melcarne A., Rimondini R., Romeo G., Bonora E.;
RT   "The tyrosine kinase receptor RET interacts in vivo with aryl
RT   hydrocarbon receptor-interacting protein to alter survivin
RT   availability.";
RL   J. Clin. Endocrinol. Metab. 94:2571-2578(2009).
RN   [21]
RP   INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3.
RX   PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055;
RA   Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H.,
RA   Tam P.K.H., Garcia-Barcelo M.M.;
RT   "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and
RT   Pax3.";
RL   J. Pediatr. Surg. 44:1904-1912(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS.
RX   PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014;
RA   Ma Q.;
RT   "RETouching upon mechanoreceptors.";
RL   Neuron 64:773-776(2009).
RN   [24]
RP   ENZYME REGULATION, AND REVIEW ON KINASE INHIBITORS.
RX   PubMed=20605972; DOI=10.1210/er.2009-0031;
RA   Ye L., Santarpia L., Gagel R.F.;
RT   "The evolving field of tyrosine kinase inhibitors in the treatment of
RT   endocrine tumors.";
RL   Endocr. Rev. 31:578-599(2010).
RN   [25]
RP   ENZYME REGULATION.
RX   PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017;
RA   Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C.,
RA   Kunick C.;
RT   "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-
RT   (3-thienyl)nicotinonitrile scaffold.";
RL   Eur. J. Med. Chem. 45:2919-2927(2010).
RN   [26]
RP   FUNCTION IN PITUITARY.
RX   PubMed=20616503; DOI=10.1159/000318502;
RA   Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E.,
RA   Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.;
RT   "Functional role of the RET dependence receptor, GFRa co-receptors and
RT   ligands in the pituitary.";
RL   Front. Horm. Res. 38:127-138(2010).
RN   [27]
RP   FUNCTION IN CELL ADHESION/MIGRATION.
RX   PubMed=20702524; DOI=10.1210/jc.2010-0771;
RA   Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.;
RT   "RET-mediated cell adhesion and migration require multiple integrin
RT   subunits.";
RL   J. Clin. Endocrinol. Metab. 95:E342-E346(2010).
RN   [28]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19823924; DOI=10.1007/s10895-009-0548-x;
RA   Richardson D.S., Mulligan L.M.;
RT   "Direct visualization of vesicle maturation and plasma membrane
RT   protein trafficking.";
RL   J. Fluoresc. 20:401-405(2010).
RN   [29]
RP   ENZYME REGULATION.
RX   PubMed=21134556; DOI=10.1016/j.surg.2010.09.026;
RA   Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.;
RT   "A novel RET inhibitor with potent efficacy against medullary thyroid
RT   cancer in vivo.";
RL   Surgery 148:1228-1236(2010).
RN   [30]
RP   FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC
RP   PROCESSING BY CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF
RP   ASP-707; LYS-758 AND 708-ALA--SER-1114, AND SUBUNIT.
RX   PubMed=21357690; DOI=10.1074/jbc.M110.195461;
RA   Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.;
RT   "RET modulates cell adhesion via its cleavage by caspase in
RT   sympathetic neurons.";
RL   J. Biol. Chem. 286:14628-14638(2011).
RN   [31]
RP   INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION.
RX   PubMed=21454698; DOI=10.1074/jbc.M110.168500;
RA   Plaza-Menacho I., Morandi A., Mologni L., Boender P.,
RA   Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P.,
RA   McDonald N.Q., Isacke C.M.;
RT   "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain,
RT   priming a direct and reciprocal RET-FAK transactivation mechanism.";
RL   J. Biol. Chem. 286:17292-17302(2011).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX
RP   WITH INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   PHOSPHORYLATION AT TYR-900 AND TYR-905.
RX   PubMed=16928683; DOI=10.1074/jbc.M605604200;
RA   Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S.,
RA   Santoro M., Ibanez C.F., McDonald N.Q.;
RT   "Structure and chemical inhibition of the RET tyrosine kinase
RT   domain.";
RL   J. Biol. Chem. 281:33577-33587(2006).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH
RP   INHIBITORS, ENZYME REGULATION, AND PHOSPHORYLATION AT TYR-905.
RX   PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011;
RA   Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S.,
RA   Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q.,
RA   Lucchini V., Gambacorti-Passerini C.;
RT   "Synthesis, structure-activity relationship and crystallographic
RT   studies of 3-substituted indolin-2-one RET inhibitors.";
RL   Bioorg. Med. Chem. 18:1482-1496(2010).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT
RP   ASN-151, AND DISULFIDE BOND.
RX   PubMed=20473317; DOI=10.1038/nsmb.1808;
RA   Kjaer S., Hanrahan S., Totty N., McDonald N.Q.;
RT   "Mammal-restricted elements predispose human RET to folding impairment
RT   by HSCR mutations.";
RL   Nat. Struct. Mol. Biol. 17:726-731(2010).
RN   [35]
RP   REVIEW ON HSCR VARIANTS.
RX   PubMed=9359036;
RA   Hofstra R.M.W., Osinga J., Buys C.H.C.M.;
RT   "Mutations in Hirschsprung disease: when does a mutation contribute to
RT   the phenotype.";
RL   Eur. J. Hum. Genet. 5:180-185(1997).
RN   [36]
RP   REVIEW ON VARIANTS.
RX   PubMed=9067749;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.0.CO;2-M;
RA   Eng C., Mulligan L.M.;
RT   "Mutations of the RET proto-oncogene in the multiple endocrine
RT   neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:97-109(1997).
RN   [37]
RP   VARIANTS MEN2A/MTC TRP-611; SER-618; ARG-620; TYR-620 AND ARG-634.
RX   PubMed=8103403; DOI=10.1093/hmg/2.7.851;
RA   Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K.,
RA   Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.;
RT   "Mutations in the RET proto-oncogene are associated with MEN 2A and
RT   FMTC.";
RL   Hum. Mol. Genet. 2:851-856(1993).
RN   [38]
RP   VARIANTS MEN2A GLY-618; 632-ASP--ARG-634; GLY-634; PHE-634; TYR-634
RP   AND SER-634.
RX   PubMed=8099202; DOI=10.1038/363458a0;
RA   Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C.,
RA   Gardner E., Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A.,
RA   Telenius H., Tunnacliffe A., Ponder B.A.J.;
RT   "Germ-line mutations of the RET proto-oncogene in multiple endocrine
RT   neoplasia type 2A.";
RL   Nature 363:458-460(1993).
RN   [39]
RP   VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND
RP   LEU-973.
RX   PubMed=7704557;
RA   Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I.,
RA   Pasini B., Tocco T., Lerone M., Cywes S., Moore S.,
RA   Vanderwinden J.-M., Abramowicz M.J., Kristoffersson U., Larsson L.T.,
RA   Hamel B.C.J., Silengo M., Martucciello G., Romeo G.;
RT   "Heterogeneity and low detection rate of RET mutations in Hirschsprung
RT   disease.";
RL   Eur. J. Hum. Genet. 2:272-280(1994).
RN   [40]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7911697; DOI=10.1093/hmg/3.2.237;
RA   Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S.,
RA   Ponder M.A., Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A.,
RA   Ponder B.A.J.;
RT   "Point mutation within the tyrosine kinase domain of the RET proto-
RT   oncogene in multiple endocrine neoplasia type 2B and related sporadic
RT   tumours.";
RL   Hum. Mol. Genet. 3:237-241(1994).
RN   [41]
RP   VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634;
RP   GLY-634 AND TYR-634.
RX   PubMed=7915165; DOI=10.1093/hmg/3.4.635;
RA   Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N.,
RA   Schuster M.K., Browden D.W., Mao J.-I., Noll W.W.;
RT   "Germline RET mutations in MEN 2A and FMTC and their detection by
RT   simple DNA diagnostic tests.";
RL   Hum. Mol. Genet. 3:635-638(1994).
RN   [42]
RP   VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620.
RX   PubMed=7849720; DOI=10.1093/hmg/3.10.1895;
RA   Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B.,
RA   Hruban R.H., Sidransky D.;
RT   "RET proto-oncogene mutations in inherited and sporadic medullary
RT   thyroid cancer.";
RL   Hum. Mol. Genet. 3:1895-1897(1994).
RN   [43]
RP   VARIANTS MTC, AND VARIANTS MEN2A.
RX   PubMed=7874109; DOI=10.1093/hmg/3.11.1939;
RA   Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N.,
RA   Calmettes C., Modigliani E., Lenoir G.M.;
RT   "RET proto-oncogene mutations in French MEN 2A and FMTC families.";
RL   Hum. Mol. Genet. 3:1939-1943(1994).
RN   [44]
RP   VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618,
RP   AND VARIANT MTC ARG-620.
RX   PubMed=7881414; DOI=10.1093/hmg/3.12.2163;
RA   Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J.,
RA   Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A.,
RA   Venter D.J., Munnich A., Ponder B.A.J.;
RT   "Diverse phenotypes associated with exon 10 mutations of the RET
RT   proto-oncogene.";
RL   Hum. Mol. Genet. 3:2163-2167(1994).
RN   [45]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906866; DOI=10.1038/367375a0;
RA   Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P.,
RA   Stelwagen T., Luo Y., Pasini B., Hoeppener J.W.M.,
RA   Ploos van Amstel H.K., Romeo G., Lips C.J.M., Buys C.H.C.M.;
RT   "A mutation in the RET proto-oncogene associated with multiple
RT   endocrine neoplasia type 2B and sporadic medullary thyroid
RT   carcinoma.";
RL   Nature 367:375-376(1994).
RN   [46]
RP   VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972.
RX   PubMed=8114938; DOI=10.1038/367377a0;
RA   Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I.,
RA   Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.;
RT   "Point mutations affecting the tyrosine kinase domain of the RET
RT   proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:377-378(1994).
RN   [47]
RP   VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393.
RX   PubMed=8114939; DOI=10.1038/367378a0;
RA   Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L.,
RA   Holder S., Nihoul-Fkete C., Ponder B.A.J., Munnich A.;
RT   "Mutations of the RET proto-oncogene in Hirschsprung's disease.";
RL   Nature 367:378-380(1994).
RN   [48]
RP   VARIANT MEN2B THR-918.
RX   PubMed=7906417; DOI=10.1073/pnas.91.4.1579;
RA   Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E.,
RA   Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.;
RT   "Single missense mutation in the tyrosine kinase catalytic domain of
RT   the RET protooncogene is associated with multiple endocrine neoplasia
RT   type 2B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994).
RN   [49]
RP   VARIANTS MTC; MEN2A AND MEN2B.
RX   PubMed=8625130;
RX   DOI=10.1002/1097-0142(19950801)76:3<479::AID-CNCR2820760319>3.0.CO;2-M;
RA   Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G.,
RA   Colomer A., Roth J., Heitz P.U.;
RT   "Analysis of RET protooncogene point mutations distinguishes heritable
RT   from nonheritable medullary thyroid carcinomas.";
RL   Cancer 76:479-489(1995).
RN   [50]
RP   VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634.
RX   PubMed=7860065; DOI=10.1007/BF00209399;
RA   Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S.,
RA   Takami H., Hikiji K., Nakamura Y.;
RT   "Germline mutations of the RET proto-oncogene in eight Japanese
RT   patients with multiple endocrine neoplasia type 2A (MEN2A).";
RL   Hum. Genet. 95:187-190(1995).
RN   [51]
RP   VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND
RP   VARIANT CYS-982.
RC   TISSUE=Blood;
RX   PubMed=7633441; DOI=10.1093/hmg/4.5.821;
RA   Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W.,
RA   Buys C.H.C.M., Cass D.T., Chakravarti A.;
RT   "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung
RT   disease.";
RL   Hum. Mol. Genet. 4:821-830(1995).
RN   [52]
RP   VARIANTS HSCR1.
RC   TISSUE=Leukocyte;
RX   PubMed=7581377; DOI=10.1093/hmg/4.8.1381;
RA   Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J.,
RA   Boutrand L., Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J.,
RA   Lyonnet S.;
RT   "Diversity of RET proto-oncogene mutations in familial and sporadic
RT   Hirschsprung disease.";
RL   Hum. Mol. Genet. 4:1381-1386(1995).
RN   [53]
RP   VARIANT MEN2B THR-918, AND VARIANT TYR-922.
RX   PubMed=8595427; DOI=10.1093/hmg/4.10.1987;
RA   Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E.,
RA   Goodfellow P.J.;
RT   "Two maternally derived missense mutations in the tyrosine kinase
RT   domain of the RET protooncogene in a patient with de novo MEN 2B.";
RL   Hum. Mol. Genet. 4:1987-1988(1995).
RN   [54]
RP   VARIANT MTC ASP-768.
RX   PubMed=7845675;
RA   Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J.,
RA   Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D.,
RA   Ponder B.A.J.;
RT   "A novel point mutation in the tyrosine kinase domain of the RET
RT   proto-oncogene in sporadic medullary thyroid carcinoma and in a family
RT   with FMTC.";
RL   Oncogene 10:509-513(1995).
RN   [55]
RP   VARIANTS MTC ASP-768 AND LEU-804.
RX   PubMed=7784092;
RA   Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T.,
RA   Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J.,
RA   Lenoir G.M., Romeo G.;
RT   "RET mutations in exons 13 and 14 of FMTC patients.";
RL   Oncogene 10:2415-2419(1995).
RN   [56]
RP   VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND
RP   PRO-1061.
RA   Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C.,
RA   Buys C.H.C.M.;
RT   "Mutations in three genes are found associated with the development of
RT   Hirschsprung disease: RET, EDNRB and EDN3.";
RL   Am. J. Hum. Genet. 59:A263-A263(1996).
RN   [57]
RP   VARIANTS HSCR1 PRO-40 AND PRO-765.
RX   PubMed=9043870;
RA   Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.;
RT   "Prevalence and parental origin of de novo RET mutations in
RT   Hirschsprung's disease.";
RL   Eur. J. Hum. Genet. 4:356-358(1996).
RN   [58]
RP   VARIANTS MTC/MEN2A.
RX   PubMed=8557249; DOI=10.1007/BF00218825;
RA   Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M.,
RA   Lips C.J.M., van Amstel H.K.P.;
RT   "Mutation analysis of the RET proto-oncogene in Dutch families with
RT   MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation
RT   for MEN 2A.";
RL   Hum. Genet. 97:11-14(1996).
RN   [59]
RP   VARIANTS MEN2A, VARIANT MTC ASP-768, AND VARIANT MEN2B THR-918.
RX   PubMed=8807338;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.3.CO;2-N;
RA   Kambouris M., Jackson C.E., Feldman G.L.;
RT   "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial
RT   medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex
RT   analyses of RET proto-oncogene mutations.";
RL   Hum. Mutat. 8:64-70(1996).
RN   [60]
RP   VARIANTS MEN2A.
RX   PubMed=8626834; DOI=10.1210/jcem.81.5.8626834;
RA   Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H.,
RA   Haase R., Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F.,
RA   Ritter M.M., Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U.,
RA   Brabant G., Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J.,
RA   Doerr A.G., Hoehne T., Hoernig-Franz I., Huefner M., Kress J.,
RA   Langer H.J., Lottermoser K., Schweikert H.U., Kusterer K., Menken U.,
RA   Mercier J., Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.;
RT   "Mutations of the ret protooncogene in German multiple endocrine
RT   neoplasia families: relation between genotype and phenotype.";
RL   J. Clin. Endocrinol. Metab. 81:1780-1783(1996).
RN   [61]
RP   VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS.
RX   PubMed=9097963; DOI=10.1093/hmg/6.4.587;
RA   Hoeppner W., Ritter M.M.;
RT   "A duplication of 12 bp in the critical cysteine rich domain of the
RT   RET proto-oncogene results in a distinct phenotype of multiple
RT   endocrine neoplasia type 2A.";
RL   Hum. Mol. Genet. 6:587-590(1997).
RN   [62]
RP   VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791.
RX   PubMed=9090527;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:3<243::AID-HUMU5>3.3.CO;2-N;
RA   Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R.,
RA   Pasini B., Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T.,
RA   Casasa J.M., Cass D.T., Abramowicz M.J., Vanderwinden J.-M.,
RA   Kravcenkiene I., Baric I., Silengo M., Martucciello G., Romeo G.;
RT   "Frequency of RET mutations in long- and short-segment Hirschsprung
RT   disease.";
RL   Hum. Mutat. 9:243-249(1997).
RN   [63]
RP   VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618.
RX   PubMed=9259198;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:2<155::AID-HUMU7>3.3.CO;2-G;
RA   Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S.,
RA   Grynberg E., Yakobson E., Graff E., Lapidot M.;
RT   "Cys 618 Arg mutation in the RET proto-oncogene associated with
RT   familial medullary thyroid carcinoma and maternally transmitted
RT   Hirschsprung's disease suggesting a role for imprinting.";
RL   Hum. Mutat. 10:155-159(1997).
RN   [64]
RP   VARIANT MEN2B PHE-883.
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=9360560; DOI=10.1210/jcem.82.11.4508;
RA   Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M.,
RA   Mulligan L.M., Zajac J.D., Robinson B.G., Eng C.;
RT   "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene
RT   in multiple endocrine neoplasia type 2B without codon 918 mutation.";
RL   J. Clin. Endocrinol. Metab. 82:3902-3904(1997).
RN   [65]
RP   VARIANT MTC ALA-891.
RX   PubMed=9398735; DOI=10.1210/jcem.82.12.4439;
RA   Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U.,
RA   Colantuoni V., Buys C.H.C.M.;
RT   "A novel point mutation in the intracellular domain of the ret
RT   protooncogene in a family with medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 82:4176-4178(1997).
RN   [66]
RP   VARIANTS HSCR1 SER-174 AND TYR-197.
RX   PubMed=9094028; DOI=10.1016/S0022-3468(97)90616-3;
RA   Kusafuka T., Wang Y., Puri P.;
RT   "Mutation analysis of the RET, the endothelin-B receptor, and the
RT   endothelin-3 genes in sporadic cases of Hirschsprung's disease.";
RL   J. Pediatr. Surg. 32:501-504(1997).
RN   [67]
RP   VARIANTS MTC; MEN2A AND MEN2B, AND VARIANT SER-691.
RX   PubMed=9223675; DOI=10.1038/sj.onc.1201102;
RA   Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K.,
RA   Kitagawa W., Akasu H., Takami H., Tanaka S., Wells S.A. Jr.;
RT   "Novel germline RET proto-oncogene mutations associated with medullary
RT   thyroid carcinoma (MTC): mutation analysis in Japanese patients with
RT   MTC.";
RL   Oncogene 14:3103-3106(1997).
RN   [68]
RP   VARIANT MEN2B PHE-883.
RX   PubMed=9294615; DOI=10.1038/sj.onc.1201481;
RA   Smith D.P., Houghton C., Ponder B.A.J.;
RT   "Germline mutation of RET codon 883 in two cases of de novo MEN 2B.";
RL   Oncogene 15:1213-1217(1997).
RN   [69]
RP   VARIANT CCHS LEU-1039, AND VARIANT SER-691.
RX   PubMed=9497256; DOI=10.1086/301759;
RA   Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M.,
RA   Gaultier C., Munnich A., Lyonnet S.;
RT   "Mutations of the RET-GDNF signaling pathway in Ondine's curse.";
RL   Am. J. Hum. Genet. 62:715-717(1998).
RN   [70]
RP   VARIANT MTC GLY-611.
RX   PubMed=9677065;
RX   DOI=10.1002/(SICI)1096-8628(19980707)78:3<271::AID-AJMG13>3.0.CO;2-C;
RA   Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V.,
RA   Rivera-Fillat F.;
RT   "Novel point mutation in exon 10 of the RET proto-oncogene in a family
RT   with medullary thyroid carcinoma.";
RL   Am. J. Med. Genet. 78:271-273(1998).
RN   [71]
RP   VARIANT CYS-982.
RX   PubMed=9760196; DOI=10.1007/s004390050797;
RA   Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.;
RT   "Phenotypic variation in a family with mutations in two Hirschsprung-
RT   related genes (RET and endothelin receptor B).";
RL   Hum. Genet. 103:145-148(1998).
RN   [72]
RP   VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS
RP   HSCR1 TYR-609; SER-618; ARG-620 AND TRP-620.
RX   PubMed=9384613; DOI=10.1093/hmg/7.1.129;
RA   Decker R.A., Peacock M.L., Watson P.;
RT   "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10
RT   genotypes and strong genotype-phenotype correlation.";
RL   Hum. Mol. Genet. 7:129-134(1998).
RN   [73]
RP   VARIANT MEN2A CYS-ARG-THR-636 INS.
RX   PubMed=9452064;
RA   Hoeppner W., Dralle H., Brabant G.;
RT   "Duplication of 9 base pairs in the critical cysteine-rich domain of
RT   the RET proto-oncogene causes multiple endocrine neoplasia type 2A.";
RL   Hum. Mutat. Suppl. 1:S128-S130(1998).
RN   [74]
RP   VARIANT MTC MET-804.
RX   PubMed=9452077;
RA   Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E.,
RA   Colantuoni V.;
RT   "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET
RT   proto-oncogene in two families affected by familial medullary thyroid
RT   carcinoma.";
RL   Hum. Mutat. Suppl. 1:S167-S171(1998).
RN   [75]
RP   VARIANTS MTC/MEN2A PHE-790 AND PHE-791.
RX   PubMed=9506724; DOI=10.1210/jcem.83.3.4619;
RA   Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P.,
RA   Grussendorf M., Raue F., Ritter M.M., Hoeppner W.;
RT   "A new hot spot for mutations in the ret protooncogene causing
RT   familial medullary thyroid carcinoma and multiple endocrine neoplasia
RT   type 2A.";
RL   J. Clin. Endocrinol. Metab. 83:770-774(1998).
RN   [76]
RP   VARIANTS MTC AND MEN2A.
RX   PubMed=9621513; DOI=10.1007/s100380050048;
RA   Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A.,
RA   Nakamura Y.;
RT   "Mutational analysis of the RET proto-oncogene in 71 Japanese patients
RT   with medullary thyroid carcinoma.";
RL   J. Hum. Genet. 43:101-106(1998).
RN   [77]
RP   VARIANTS HSCR1 LYS-626 AND GLN-813.
RX   PubMed=10090908; DOI=10.1086/302329;
RA   Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A.,
RA   Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A.,
RA   Ceccherini I.;
RT   "Double heterozygosity for a RET substitution interfering with
RT   splicing and an EDNRB missense mutation in Hirschsprung disease.";
RL   Am. J. Hum. Genet. 64:1216-1221(1999).
RN   [78]
RP   VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061.
RX   PubMed=10484767; DOI=10.1093/hmg/8.11.1989;
RA   Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S.,
RA   Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.;
RT   "Two distinct mutations of the RET receptor causing Hirschsprung's
RT   disease impair the binding of signalling effectors to a
RT   multifunctional docking site.";
RL   Hum. Mol. Genet. 8:1989-1999(1999).
RN   [79]
RP   VARIANT MTC GLU-GLU-CYS-531 INS.
RX   PubMed=10323403; DOI=10.1210/jcem.84.5.5665;
RA   Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P.,
RA   Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.;
RT   "A novel 9-base pair duplication in RET exon 8 in familial medullary
RT   thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:1700-1704(1999).
RN   [80]
RP   VARIANT MEN2A GLY-640.
RX   PubMed=10522989; DOI=10.1210/jcem.84.10.6056;
RA   Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D.,
RA   Bellastella A., Colantuoni V.;
RT   "A novel case of multiple endocrine neoplasia type 2A associated with
RT   two de novo mutations of the RET protooncogene.";
RL   J. Clin. Endocrinol. Metab. 84:3522-3527(1999).
RN   [81]
RP   VARIANTS MTC MET-804 AND LEU-844.
RX   PubMed=10826520; DOI=10.1055/s-2000-5806;
RA   Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.;
RT   "A RET double mutation in the germline of a kindred with FMTC.";
RL   Exp. Clin. Endocrinol. Diabetes 108:128-132(2000).
RN   [82]
RP   VARIANT GLN-600.
RX   PubMed=10612852;
RX   DOI=10.1002/(SICI)1098-1004(200001)15:1<122::AID-HUMU41>3.0.CO;2-7;
RA   Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G.,
RA   Borrego S.;
RT   "A new germline mutation, R600Q, within the coding region of RET
RT   proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?";
RL   Hum. Mutat. 15:122-122(2000).
RN   [83]
RP   VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394.
RX   PubMed=10618407; DOI=10.1073/pnas.97.1.268;
RA   Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D.,
RA   Buys C.H.C.M., Lyonnet S., Chakravarti A.;
RT   "A human model for multigenic inheritance: phenotypic expression in
RT   Hirschsprung disease requires both the RET gene and a new 9q31
RT   locus.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000).
RN   [84]
RP   VARIANTS MTC GLY-639; GLY-641 AND PHE-922.
RX   PubMed=11692159; DOI=10.1007/s001090100250;
RA   Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N.,
RA   Hosch S.B., Garkavtseva R.F., Izbicki J.R.;
RT   "Three novel mutations in the RET proto-oncogene.";
RL   J. Mol. Med. 79:609-612(2001).
RN   [85]
RP   VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634;
RP   TRP-634 AND PHE-791.
RX   PubMed=12000816; DOI=10.1056/NEJMoa020152;
RG   The Freiburg-Warsaw-Columbus pheochromocytoma study group;
RA   Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O.,
RA   Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K.,
RA   Januszewicz A., Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W.,
RA   Treier M., Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M.,
RA   Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M.,
RA   Peczkowska M., Szmigielski C., Eng C.;
RT   "Germ-line mutations in nonsyndromic pheochromocytoma.";
RL   N. Engl. J. Med. 346:1459-1466(2002).
RN   [86]
RP   VARIANT CCHS HIS-114.
RX   PubMed=12086152; DOI=10.1620/tjem.196.241;
RA   Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K.,
RA   Hashimoto M., Hasegawa H., Shirasawa S., Hayasaka K.;
RT   "Congenital central hypoventilation syndrome: a novel mutation of the
RT   RET gene in an isolated case.";
RL   Tohoku J. Exp. Med. 196:241-246(2002).
RN   [87]
RP   VARIANTS ASN-489; SER-691 AND CYS-982, AND VARIANTS CCHS HIS-67;
RP   HIS-114 AND GLU-432.
RX   PubMed=14566559; DOI=10.1007/s00439-003-1036-z;
RA   Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H.,
RA   Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W.,
RA   Nakamura T., Hayasaka K.;
RT   "Molecular analysis of congenital central hypoventilation syndrome.";
RL   Hum. Genet. 114:22-26(2003).
RN   [88]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [89]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489;
RP   SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [90]
RP   VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918;
RP   LEU-1049 AND SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND
RP   CHARACTERIZATION OF VARIANTS THR-198; ALA-376; HIS-394; ILE-778;
RP   SER-894; LEU-1049 AND SER-1067.
RX   PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008;
RA   Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E.,
RA   Freemerman A.J.;
RT   "Renal aplasia in humans is associated with RET mutations.";
RL   Am. J. Hum. Genet. 82:344-351(2008).
RN   [91]
RP   VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; HIS-114; GLY-145;
RP   LEU-155; PRO-175; ALA-278; PRO-278; ASN-300; GLN-313; ILE-316;
RP   LEU-339; TYR-353; GLN-360; MET-397; MET-412; ARG-423; LYS-480;
RP   GLN-595; LEU-679; GLN-694; SER-783; ARG-830; THR-907; LEU-961;
RP   VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS ASN-278 AND MET-292.
RX   PubMed=22174939; DOI=10.1371/journal.pone.0028986;
RA   So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K.,
RA   Diem N.N., Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H.,
RA   Yuan Z.W., Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L.,
RA   Chan I.H., Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C.,
RA   Cherny S.S., Tam P.K., Garcia-Barcelo M.M.;
RT   "RET mutational spectrum in Hirschsprung disease: evaluation of 601
RT   Chinese patients.";
RL   PLoS ONE 6:E28986-E28986(2011).
CC   -!- FUNCTION: Receptor tyrosine-protein kinase involved in numerous
CC       cellular mechanisms including cell proliferation, neuronal
CC       navigation, cell migration, and cell differentiation upon binding
CC       with glial cell derived neurotrophic factor family ligands.
CC       Phosphorylates PTK2/FAK1. Regulates both cell death/survival
CC       balance and positional information. Required for the molecular
CC       mechanisms orchestration during intestine organogenesis; involved
CC       in the development of enteric nervous system and renal
CC       organogenesis during embryonic life, and promotes the formation of
CC       Peyer's patch-like structures, a major component of the gut-
CC       associated lymphoid tissue. Modulates cell adhesion via its
CC       cleavage by caspase in sympathetic neurons and mediates cell
CC       migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner.
CC       Involved in the development of the neural crest. Active in the
CC       absence of ligand, triggering apoptosis through a mechanism that
CC       requires receptor intracellular caspase cleavage. Acts as a
CC       dependence receptor; in the presence of the ligand GDNF in
CC       somatotrophs (within pituitary), promotes survival and down
CC       regulates growth hormone (GH) production, but triggers apoptosis
CC       in absence of GDNF. Regulates nociceptor survival and size.
CC       Triggers the differentiation of rapidly adapting (RA)
CC       mechanoreceptors. Mediator of several diseases such as
CC       neuroendocrine cancers; these diseases are characterized by
CC       aberrant integrins-regulated cell migration.
CC       {ECO:0000269|PubMed:20064382, ECO:0000269|PubMed:20616503,
CC       ECO:0000269|PubMed:20702524, ECO:0000269|PubMed:21357690,
CC       ECO:0000269|PubMed:21454698}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Repressed by 4-(3-hydroxyanilino)-quinolines
CC       derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-
CC       thienyl) nicotinonitrile analogs, 3- and 4-substituted beta-
CC       carbolin-1-ones, vandetanib, motesanib, sorafenib (BAY 43-9006),
CC       cabozantinib (XL184), sunitinib, and withaferin A (WA).
CC       Inactivation by sorafenib both reduces kinase activity and
CC       promotes lysosomal degradation. {ECO:0000269|PubMed:17664273,
CC       ECO:0000269|PubMed:17884497, ECO:0000269|PubMed:19053769,
CC       ECO:0000269|PubMed:20117004, ECO:0000269|PubMed:20409618,
CC       ECO:0000269|PubMed:20605972, ECO:0000269|PubMed:21134556}.
CC   -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of
CC       DOK2, DOK4 and DOK5. The phosphorylated form interacts with PLCG1
CC       and GRB7. Interacts (not phosphorylated) with PTK2/FAK1 (via FERM
CC       domain). Extracellular cell-membrane anchored RET cadherin
CC       fragments form complex in neurons with reduced trophic status,
CC       preferentially at the contact sites between somas. Interacts with
CC       AIP in the pituitary gland; this interaction prevents the
CC       formation of the AIP-survivin complex. Binds to ARTN. Interacts
CC       (inactive) with CBLC and CD2AP; dissociates upon activation by
CC       GDNF which increases CBLC:CD2AP interaction.
CC       {ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:18753381,
CC       ECO:0000269|PubMed:19366855, ECO:0000269|PubMed:20117004,
CC       ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698}.
CC   -!- INTERACTION:
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-2480756, EBI-945833;
CC       P19174:PLCG1; NbExp=2; IntAct=EBI-2480756, EBI-79387;
CC       Q62985:Sh2b1 (xeno); NbExp=3; IntAct=EBI-2480756, EBI-7395583;
CC       P40763:STAT3; NbExp=3; IntAct=EBI-2480756, EBI-518675;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19823924};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:19823924}.
CC       Endosome membrane {ECO:0000269|PubMed:19823924}; Single-pass type
CC       I membrane protein {ECO:0000269|PubMed:19823924}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=RET51;
CC         IsoId=P07949-1; Sequence=Displayed;
CC         Note=No experimental confirmation available.;
CC       Name=2; Synonyms=RET9;
CC         IsoId=P07949-2; Sequence=VSP_040735;
CC   -!- INDUCTION: Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3.
CC       {ECO:0000269|PubMed:19853745}.
CC   -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon
CC       ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015
CC       and Tyr-1062. {ECO:0000269|PubMed:11061555,
CC       ECO:0000269|PubMed:14711813, ECO:0000269|PubMed:16778204,
CC       ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004}.
CC   -!- PTM: Proteolytically cleaved by caspase-3. The soluble RET kinase
CC       fragment is able to induce cell death. The extracellular cell-
CC       membrane anchored RET cadherin fragment accelerates cell adhesion
CC       in sympathetic neurons. {ECO:0000269|PubMed:21357690}.
CC   -!- POLYMORPHISM: The Cys-982 polymorphism may be associated with an
CC       increased risk for developing Hirschsprung disease.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       Note=The disease may be caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder
CC       of neural crest development characterized by absence of enteric
CC       ganglia along a variable length of the intestine. It is the most
CC       common cause of congenital intestinal obstruction. Early symptoms
CC       range from complete acute neonatal obstruction, characterized by
CC       vomiting, abdominal distention and failure to pass stool, to
CC       chronic constipation in the older child.
CC       {ECO:0000269|PubMed:10090908, ECO:0000269|PubMed:10484767,
CC       ECO:0000269|PubMed:10618407, ECO:0000269|PubMed:22174939,
CC       ECO:0000269|PubMed:7581377, ECO:0000269|PubMed:7633441,
CC       ECO:0000269|PubMed:7704557, ECO:0000269|PubMed:7881414,
CC       ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:8114939,
CC       ECO:0000269|PubMed:9043870, ECO:0000269|PubMed:9090527,
CC       ECO:0000269|PubMed:9094028, ECO:0000269|PubMed:9259198,
CC       ECO:0000269|PubMed:9384613, ECO:0000269|Ref.56}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare
CC       tumor derived from the C cells of the thyroid. Three hereditary
CC       forms are known, that are transmitted in an autosomal dominant
CC       fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple
CC       neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which
CC       occurs in 25-30% of MTC cases and where MTC is the only clinical
CC       manifestation. {ECO:0000269|PubMed:10323403,
CC       ECO:0000269|PubMed:10826520, ECO:0000269|PubMed:11692159,
CC       ECO:0000269|PubMed:7784092, ECO:0000269|PubMed:7845675,
CC       ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7874109,
CC       ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165,
CC       ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:8557249,
CC       ECO:0000269|PubMed:8625130, ECO:0000269|PubMed:8807338,
CC       ECO:0000269|PubMed:9223675, ECO:0000269|PubMed:9259198,
CC       ECO:0000269|PubMed:9398735, ECO:0000269|PubMed:9452077,
CC       ECO:0000269|PubMed:9506724, ECO:0000269|PubMed:9621513,
CC       ECO:0000269|PubMed:9677065}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon
CC       inherited cancer syndrome characterized by predisposition to MTC
CC       and phaeochromocytoma which is associated with marfanoid habitus,
CC       mucosal neuromas, skeletal and ophthalmic abnormalities, and
CC       ganglioneuromas of the intestine tract. Then the disease
CC       progresses rapidly with the development of metastatic MTC and a
CC       pheochromocytome in 50% of cases. {ECO:0000269|PubMed:7906417,
CC       ECO:0000269|PubMed:7906866, ECO:0000269|PubMed:7911697,
CC       ECO:0000269|PubMed:8595427, ECO:0000269|PubMed:8807338,
CC       ECO:0000269|PubMed:9294615, ECO:0000269|PubMed:9360560}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-
CC       producing tumor of chromaffin tissue of the adrenal medulla or
CC       sympathetic paraganglia. The cardinal symptom, reflecting the
CC       increased secretion of epinephrine and norepinephrine, is
CC       hypertension, which may be persistent or intermittent.
CC       {ECO:0000269|PubMed:12000816}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most
CC       frequent form of medullary thyroid cancer (MTC). It is an
CC       inherited cancer syndrome characterized by MTC, phaeochromocytoma
CC       and/or hyperparathyroidism. {ECO:0000269|PubMed:10522989,
CC       ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7874109,
CC       ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165,
CC       ECO:0000269|PubMed:8099202, ECO:0000269|PubMed:8103403,
CC       ECO:0000269|PubMed:8626834, ECO:0000269|PubMed:8807338,
CC       ECO:0000269|PubMed:9097963, ECO:0000269|PubMed:9384613,
CC       ECO:0000269|PubMed:9452064}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Various chromosomal aberrations involving RET are
CC       known. Some of them have been found in papillary thyroid
CC       carcinomas (PTCs) (PubMed:12787916, PubMed:2406025,
CC       PubMed:10980597, PubMed:10439047). Inversion inv(10)(q11.2;q21)
CC       generates the RET/CCDC6 (PTC1) oncogene (PubMed:2406025).
CC       Inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3)
CC       oncogene. Translocation t(10;14)(q11;q32) with GOLGA5 generates
CC       the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021). Translocation
CC       t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion
CC       (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with
CC       TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916).
CC       Translocation t(1;10)(p13;q11) with TRIM33 generates the
CC       TRIM33/RET (PTC7) oncogene (PubMed:10439047). Translocation
CC       t(7;10)(q32;q11) with TRIM24/TIF1 generates the TRIM24/RET (PTC6)
CC       oncogene (PubMed:10439047). Translocation t(6;10)(p21.3;q11.2)
CC       with TRIM27/RFP generates the TRIM27/RET oncogene
CC       (PubMed:3037315). {ECO:0000269|PubMed:10439047,
CC       ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:12787916,
CC       ECO:0000269|PubMed:2406025, ECO:0000269|PubMed:2734021,
CC       ECO:0000269|PubMed:3037315}.
CC   -!- DISEASE: Note=Mutations in RET have been detected in patients with
CC       renal agenesis suggesting a possible involvement of this gene in
CC       disease pathogenesis.
CC   -!- DISEASE: Congenital central hypoventilation syndrome (CCHS)
CC       [MIM:209880]: Rare disorder characterized by abnormal control of
CC       respiration in the absence of neuromuscular or lung disease, or an
CC       identifiable brain stem lesion. A deficiency in autonomic control
CC       of respiration results in inadequate or negligible ventilatory and
CC       arousal responses to hypercapnia and hypoxemia.
CC       {ECO:0000269|PubMed:12086152, ECO:0000269|PubMed:14566559,
CC       ECO:0000269|PubMed:9497256}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Treatment with withaferin A (WA) leads tumor
CC       regression in medullary thyroid carcinomas (MTC).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA36524.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAA36786.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAA33787.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAC14882.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/RETID76.html";
CC   -!- WEB RESOURCE: Name=MEN2 RET database;
CC       URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK291807; BAF84496.1; -; mRNA.
DR   EMBL; AC010864; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004257; AAH04257.1; -; mRNA.
DR   EMBL; X15262; CAA33333.1; -; mRNA.
DR   EMBL; X12949; CAA31408.1; -; mRNA.
DR   EMBL; M16029; AAA36786.1; ALT_INIT; mRNA.
DR   EMBL; X15786; CAA33787.1; ALT_INIT; mRNA.
DR   EMBL; M31213; AAA36524.1; ALT_INIT; mRNA.
DR   EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA.
DR   CCDS; CCDS53525.1; -. [P07949-2]
DR   CCDS; CCDS7200.1; -. [P07949-1]
DR   PIR; A27203; TVHURE.
DR   PIR; A34630; A34630.
DR   PIR; B34735; B34735.
DR   PIR; S05582; S05582.
DR   RefSeq; NP_065681.1; NM_020630.4. [P07949-2]
DR   RefSeq; NP_066124.1; NM_020975.4. [P07949-1]
DR   UniGene; Hs.350321; -.
DR   PDB; 1XPD; Model; -; A=709-1013.
DR   PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013.
DR   PDB; 2IVT; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2IVU; X-ray; 2.50 A; A=705-1013.
DR   PDB; 2IVV; X-ray; 2.25 A; A=705-1013.
DR   PDB; 2X2K; X-ray; 2.60 A; A=705-1013.
DR   PDB; 2X2L; X-ray; 2.00 A; A=705-1013.
DR   PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013.
DR   PDB; 2X2U; X-ray; 2.00 A; A=29-270.
DR   PDB; 4CKI; X-ray; 2.12 A; A=705-1013.
DR   PDB; 4CKJ; X-ray; 1.65 A; A=705-1013.
DR   PDB; 4UX8; EM; 24.00 A; A/B=29-635.
DR   PDB; 5AMN; X-ray; 2.57 A; A=705-1012.
DR   PDB; 5FM2; X-ray; 3.30 A; A=659-1013.
DR   PDB; 5FM3; X-ray; 2.95 A; A=659-1013.
DR   PDBsum; 1XPD; -.
DR   PDBsum; 2IVS; -.
DR   PDBsum; 2IVT; -.
DR   PDBsum; 2IVU; -.
DR   PDBsum; 2IVV; -.
DR   PDBsum; 2X2K; -.
DR   PDBsum; 2X2L; -.
DR   PDBsum; 2X2M; -.
DR   PDBsum; 2X2U; -.
DR   PDBsum; 4CKI; -.
DR   PDBsum; 4CKJ; -.
DR   PDBsum; 4UX8; -.
DR   PDBsum; 5AMN; -.
DR   PDBsum; 5FM2; -.
DR   PDBsum; 5FM3; -.
DR   ProteinModelPortal; P07949; -.
DR   SMR; P07949; -.
DR   BioGrid; 111911; 43.
DR   DIP; DIP-41449N; -.
DR   IntAct; P07949; 29.
DR   MINT; MINT-1217685; -.
DR   STRING; 9606.ENSP00000347942; -.
DR   BindingDB; P07949; -.
DR   ChEMBL; CHEMBL2041; -.
DR   DrugBank; DB08764; 4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB05216; MP470.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   GuidetoPHARMACOLOGY; 2185; -.
DR   iPTMnet; P07949; -.
DR   PhosphoSitePlus; P07949; -.
DR   BioMuta; RET; -.
DR   DMDM; 547807; -.
DR   EPD; P07949; -.
DR   MaxQB; P07949; -.
DR   PaxDb; P07949; -.
DR   PeptideAtlas; P07949; -.
DR   PRIDE; P07949; -.
DR   TopDownProteomics; P07949-2; -. [P07949-2]
DR   DNASU; 5979; -.
DR   Ensembl; ENST00000340058; ENSP00000344798; ENSG00000165731. [P07949-2]
DR   Ensembl; ENST00000355710; ENSP00000347942; ENSG00000165731. [P07949-1]
DR   GeneID; 5979; -.
DR   KEGG; hsa:5979; -.
DR   UCSC; uc001jak.2; human. [P07949-1]
DR   CTD; 5979; -.
DR   DisGeNET; 5979; -.
DR   GeneCards; RET; -.
DR   GeneReviews; RET; -.
DR   HGNC; HGNC:9967; RET.
DR   HPA; CAB002581; -.
DR   HPA; CAB018342; -.
DR   HPA; HPA008356; -.
DR   HPA; HPA008495; -.
DR   MalaCards; RET; -.
DR   MIM; 114500; phenotype.
DR   MIM; 142623; phenotype.
DR   MIM; 155240; phenotype.
DR   MIM; 162300; phenotype.
DR   MIM; 164761; gene.
DR   MIM; 171300; phenotype.
DR   MIM; 171400; phenotype.
DR   MIM; 209880; phenotype.
DR   neXtProt; NX_P07949; -.
DR   OpenTargets; ENSG00000165731; -.
DR   Orphanet; 1848; Bilateral renal agenesis.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 99803; Haddad syndrome.
DR   Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma.
DR   Orphanet; 388; Hirschsprung disease.
DR   Orphanet; 247698; Multiple endocrine neoplasia type 2A.
DR   Orphanet; 247709; Multiple endocrine neoplasia type 2B.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   Orphanet; 93100; Unilateral renal agenesis.
DR   PharmGKB; PA34335; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000010301; -.
DR   HOVERGEN; HBG002609; -.
DR   InParanoid; P07949; -.
DR   KO; K05126; -.
DR   OMA; WRQGDGK; -.
DR   OrthoDB; EOG091G0CQZ; -.
DR   PhylomeDB; P07949; -.
DR   TreeFam; TF317640; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   SignaLink; P07949; -.
DR   SIGNOR; P07949; -.
DR   ChiTaRS; RET; human.
DR   EvolutionaryTrace; P07949; -.
DR   GeneWiki; RET_proto-oncogene; -.
DR   GenomeRNAi; 5979; -.
DR   PRO; PR:P07949; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000165731; -.
DR   CleanEx; HS_RET; -.
DR   ExpressionAtlas; P07949; baseline and differential.
DR   Genevisible; P07949; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; IEA:Ensembl.
DR   GO; GO:0010008; C:endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0098797; C:plasma membrane protein complex; IDA:CAFA.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IDA:FlyBase.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004872; F:receptor activity; TAS:ProtInc.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl.
DR   GO; GO:0048484; P:enteric nervous system development; IEA:Ensembl.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro.
DR   GO; GO:0060384; P:innervation; IEA:Ensembl.
DR   GO; GO:0097021; P:lymphocyte migration into lymphoid organs; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
DR   GO; GO:0007158; P:neuron cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:0042551; P:neuron maturation; IEA:Ensembl.
DR   GO; GO:0061146; P:Peyer's patch morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB.
DR   GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB.
DR   GO; GO:0014042; P:positive regulation of neuron maturation; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:1903263; P:positive regulation of serine phosphorylation of STAT3 protein; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0007497; P:posterior midgut development; TAS:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0048265; P:response to pain; ISS:UniProtKB.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:Ensembl.
DR   GO; GO:0035799; P:ureter maturation; IEA:Ensembl.
DR   GO; GO:0001657; P:ureteric bud development; IEA:Ensembl.
DR   InterPro; IPR002126; Cadherin.
DR   InterPro; IPR015919; Cadherin-like.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016249; Tyr_kinase_Ret_rcpt.
DR   Pfam; PF00028; Cadherin; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49313; SSF49313; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50268; CADHERIN_2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Chromosomal rearrangement; Complete proteome;
KW   Disease mutation; Disulfide bond; Endosome; Glycoprotein;
KW   Hirschsprung disease; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     28       {ECO:0000255}.
FT   CHAIN        29   1114       Proto-oncogene tyrosine-protein kinase
FT                                receptor Ret.
FT                                /FTId=PRO_0000024450.
FT   CHAIN        29    707       Extracellular cell-membrane anchored RET
FT                                cadherin 120 kDa fragment.
FT                                /FTId=PRO_0000415292.
FT   CHAIN       708   1017       Soluble RET kinase fragment.
FT                                /FTId=PRO_0000415293.
FT   TOPO_DOM     29    635       Extracellular. {ECO:0000255}.
FT   TRANSMEM    636    657       Helical. {ECO:0000255}.
FT   TOPO_DOM    658   1114       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      168    272       Cadherin. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00043}.
FT   DOMAIN      724   1016       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     730    738       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      805    807       Inhibitors binding.
FT   ACT_SITE    874    874       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     758    758       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     892    892       Inhibitor.
FT   SITE        587    588       Breakpoint for translocation to form the
FT                                TRIM27/RET oncogene.
FT   SITE        707    708       Cleavage; by caspase-3.
FT   SITE        712    713       Breakpoint for translocation to form
FT                                PCM1-RET; RET-CCDC6; RET-GOLGA5; RET-
FT                                TRIM24 and RET-TRIM33 oncogenes.
FT   SITE       1017   1018       Cleavage; by caspase-3.
FT   MOD_RES     696    696       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     806    806       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES     809    809       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES     900    900       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16928683}.
FT   MOD_RES     905    905       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16778204,
FT                                ECO:0000269|PubMed:16928683,
FT                                ECO:0000269|PubMed:20117004}.
FT   MOD_RES     981    981       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES    1015   1015       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11061555,
FT                                ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16778204}.
FT   MOD_RES    1062   1062       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11061555,
FT                                ECO:0000269|PubMed:14711813,
FT                                ECO:0000269|PubMed:16778204}.
FT   MOD_RES    1090   1090       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   MOD_RES    1096   1096       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14711813}.
FT   CARBOHYD     98     98       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    151    151       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:20473317}.
FT   CARBOHYD    199    199       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    336    336       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    343    343       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    361    361       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    367    367       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    377    377       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    394    394       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    448    448       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    468    468       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    554    554       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    137    142       {ECO:0000269|PubMed:20473317}.
FT   VAR_SEQ    1064   1114       MSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPS
FT                                AAKLMDTFDS -> RISHAFTRF (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:3037315}.
FT                                /FTId=VSP_040735.
FT   VARIANT      20     20       P -> L (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:7633441}.
FT                                /FTId=VAR_009459.
FT   VARIANT      32     32       S -> L (in HSCR1; familial form;
FT                                dbSNP:rs76764689).
FT                                {ECO:0000269|PubMed:10618407,
FT                                ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006295.
FT   VARIANT      40     40       L -> P (in HSCR1).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:9043870}.
FT                                /FTId=VAR_009492.
FT   VARIANT      64     64       P -> L (in HSCR1; familial form;
FT                                dbSNP:rs77596424).
FT                                {ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006296.
FT   VARIANT      67     67       R -> H (in CCHS; dbSNP:rs192489011).
FT                                {ECO:0000269|PubMed:14566559}.
FT                                /FTId=VAR_018153.
FT   VARIANT      77     77       R -> C (in HSCR1).
FT                                {ECO:0000269|PubMed:10618407}.
FT                                /FTId=VAR_009460.
FT   VARIANT      93     93       G -> S (in HSCR1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:7633441}.
FT                                /FTId=VAR_006297.
FT   VARIANT     114    114       R -> C (in HSCR1; dbSNP:rs747483905).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067101.
FT   VARIANT     114    114       R -> H (in CCHS and HSCR1;
FT                                dbSNP:rs76397662).
FT                                {ECO:0000269|PubMed:12086152,
FT                                ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_018154.
FT   VARIANT     142    142       C -> S (in HSCR1; sporadic form).
FT                                /FTId=VAR_006298.
FT   VARIANT     145    145       V -> G (in HSCR1; also in a colorectal
FT                                cancer sample; somatic mutation).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_035711.
FT   VARIANT     155    155       P -> L (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067102.
FT   VARIANT     157    157       C -> Y (in HSCR1; unknown pathological
FT                                significance). {ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009461.
FT   VARIANT     163    163       R -> Q (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs149403911).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041762.
FT   VARIANT     174    174       F -> S (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:9094028}.
FT                                /FTId=VAR_009462.
FT   VARIANT     175    175       R -> P (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067103.
FT   VARIANT     180    180       R -> P (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:9090527}.
FT                                /FTId=VAR_009463.
FT   VARIANT     197    197       C -> Y (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:9094028}.
FT                                /FTId=VAR_009464.
FT   VARIANT     198    198       P -> T (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF; dbSNP:rs76736111).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044392.
FT   VARIANT     231    231       R -> H (in HSCR1; familial form;
FT                                dbSNP:rs79661516).
FT                                /FTId=VAR_006299.
FT   VARIANT     251    251       E -> K (in HSCR1; familial form;
FT                                dbSNP:rs562449603).
FT                                /FTId=VAR_006300.
FT   VARIANT     278    278       T -> A (in HSCR1; dbSNP:rs541929171).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067104.
FT   VARIANT     278    278       T -> N (found in two patients with
FT                                Hirschsprung disease; dbSNP:rs35118262).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_041763.
FT   VARIANT     278    278       T -> P (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067105.
FT   VARIANT     287    287       R -> Q (in HSCR1; sporadic form).
FT                                /FTId=VAR_006301.
FT   VARIANT     292    292       V -> M (found in patients with
FT                                Hirschsprung disease; unknown
FT                                pathological significance;
FT                                dbSNP:rs34682185).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_041764.
FT   VARIANT     300    300       D -> N (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067106.
FT   VARIANT     313    313       R -> Q (in HSCR1; dbSNP:rs77702891).
FT                                {ECO:0000269|PubMed:22174939,
FT                                ECO:0000269|PubMed:9090527}.
FT                                /FTId=VAR_009465.
FT   VARIANT     316    316       S -> I (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067107.
FT   VARIANT     330    330       R -> Q (in HSCR1; dbSNP:rs80236571).
FT                                {ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006302.
FT   VARIANT     339    339       S -> L (in HSCR1; dbSNP:rs774829203).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067108.
FT   VARIANT     353    353       D -> Y (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067109.
FT   VARIANT     359    359       N -> K (in HSCR1; unknown pathological
FT                                significance). {ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009466.
FT   VARIANT     360    360       R -> Q (in HSCR1; dbSNP:rs762472027).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067110.
FT   VARIANT     360    360       R -> W (in HSCR1).
FT                                {ECO:0000269|PubMed:10618407,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_009467.
FT   VARIANT     376    376       V -> A (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                constitutively phosphorylated; expressed
FT                                only the immature intracellular form).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044393.
FT   VARIANT     393    393       F -> L (in HSCR1; familial form;
FT                                dbSNP:rs78098482).
FT                                {ECO:0000269|PubMed:8114939}.
FT                                /FTId=VAR_006303.
FT   VARIANT     394    394       N -> H (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF). {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044394.
FT   VARIANT     394    394       N -> K (in HSCR1).
FT                                {ECO:0000269|PubMed:10618407}.
FT                                /FTId=VAR_009468.
FT   VARIANT     397    397       V -> M (in HSCR1; dbSNP:rs183729115).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067111.
FT   VARIANT     399    399       P -> L (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:7704557}.
FT                                /FTId=VAR_006304.
FT   VARIANT     412    412       V -> M (in HSCR1; dbSNP:rs746970700).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067112.
FT   VARIANT     423    423       G -> R (in HSCR1; dbSNP:rs767601598).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067113.
FT   VARIANT     432    432       A -> E (in CCHS; dbSNP:rs552057730).
FT                                {ECO:0000269|PubMed:14566559}.
FT                                /FTId=VAR_018155.
FT   VARIANT     475    475       R -> Q (in HSCR1; sporadic form;
FT                                dbSNP:rs138624658).
FT                                /FTId=VAR_006305.
FT   VARIANT     480    480       E -> K (in HSCR1; dbSNP:rs537874538).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067114.
FT   VARIANT     489    489       D -> N (in dbSNP:rs9282834).
FT                                {ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_018156.
FT   VARIANT     531    531       C -> CEEC (in MTC; familial form).
FT                                {ECO:0000269|PubMed:10323403}.
FT                                /FTId=VAR_009469.
FT   VARIANT     549    550       Missing (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067115.
FT   VARIANT     593    593       G -> E (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035712.
FT   VARIANT     595    595       E -> Q (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067116.
FT   VARIANT     600    600       R -> Q (in dbSNP:rs377767393).
FT                                {ECO:0000269|PubMed:10612852}.
FT                                /FTId=VAR_008966.
FT   VARIANT     609    609       C -> G (in MEN2A; dbSNP:rs77558292).
FT                                /FTId=VAR_009470.
FT   VARIANT     609    609       C -> R (in MEN2A; dbSNP:rs77558292).
FT                                /FTId=VAR_009471.
FT   VARIANT     609    609       C -> W (in HSCR1; familial form;
FT                                dbSNP:rs377767396).
FT                                {ECO:0000269|PubMed:7881414}.
FT                                /FTId=VAR_006307.
FT   VARIANT     609    609       C -> Y (in MTC, MEN2A and HSCR1; familial
FT                                and sporadic forms; dbSNP:rs77939446).
FT                                {ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:9384613,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_006306.
FT   VARIANT     611    611       C -> G (in MTC; familial form;
FT                                dbSNP:rs377767391).
FT                                {ECO:0000269|PubMed:9677065}.
FT                                /FTId=VAR_009472.
FT   VARIANT     611    611       C -> R (in MEN2A; dbSNP:rs377767391).
FT                                /FTId=VAR_009473.
FT   VARIANT     611    611       C -> S (in MEN2A; dbSNP:rs377767391).
FT                                /FTId=VAR_009474.
FT   VARIANT     611    611       C -> W (in MEN2A and MTC; familial form;
FT                                dbSNP:rs80069458).
FT                                {ECO:0000269|PubMed:8103403}.
FT                                /FTId=VAR_006308.
FT   VARIANT     611    611       C -> Y (in MEN2A; dbSNP:rs377767397).
FT                                /FTId=VAR_006309.
FT   VARIANT     618    618       C -> F (in MEN2A and MTC; familial form;
FT                                dbSNP:rs79781594).
FT                                /FTId=VAR_006312.
FT   VARIANT     618    618       C -> G (in MEN2A; dbSNP:rs76262710).
FT                                {ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006310.
FT   VARIANT     618    618       C -> R (in MEN2A, MTC and HSCR1;
FT                                dbSNP:rs76262710).
FT                                {ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:7881414,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:9259198}.
FT                                /FTId=VAR_006311.
FT   VARIANT     618    618       C -> S (in MEN2A, HSCR1 and MTC; familial
FT                                and sporadic forms; dbSNP:rs79781594).
FT                                {ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:7860065,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8103403,
FT                                ECO:0000269|PubMed:9384613}.
FT                                /FTId=VAR_006313.
FT   VARIANT     618    618       C -> Y (in MEN2A and MTC; familial form;
FT                                dbSNP:rs79781594).
FT                                /FTId=VAR_006314.
FT   VARIANT     620    620       C -> F (in MEN2A and MTC; familial form;
FT                                dbSNP:rs77503355).
FT                                {ECO:0000269|PubMed:7915165}.
FT                                /FTId=VAR_006318.
FT   VARIANT     620    620       C -> G (in MEN2A and MTC; familial and
FT                                sporadic forms; dbSNP:rs77316810).
FT                                /FTId=VAR_006315.
FT   VARIANT     620    620       C -> R (in MEN2A, MTC and HSCR1; familial
FT                                and sporadic forms; dbSNP:rs77316810).
FT                                {ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:7881414,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8103403,
FT                                ECO:0000269|PubMed:9090527,
FT                                ECO:0000269|PubMed:9384613,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_006316.
FT   VARIANT     620    620       C -> S (in MEN2A and MTC; familial form;
FT                                dbSNP:rs77503355).
FT                                {ECO:0000269|PubMed:7849720,
FT                                ECO:0000269|PubMed:7860065}.
FT                                /FTId=VAR_006317.
FT   VARIANT     620    620       C -> W (in MEN2A and HSCR1;
FT                                dbSNP:rs79890926).
FT                                {ECO:0000269|PubMed:9384613}.
FT                                /FTId=VAR_009475.
FT   VARIANT     620    620       C -> Y (in MEN2A; dbSNP:rs77503355).
FT                                {ECO:0000269|PubMed:8103403}.
FT                                /FTId=VAR_006319.
FT   VARIANT     626    626       Q -> K (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:10090908}.
FT                                /FTId=VAR_009476.
FT   VARIANT     630    630       C -> F (in MEN2A and MTC; familial form;
FT                                dbSNP:rs377767405).
FT                                /FTId=VAR_006320.
FT   VARIANT     630    630       C -> S (in MTC; sporadic form;
FT                                dbSNP:rs377767405).
FT                                /FTId=VAR_009477.
FT   VARIANT     630    630       C -> Y (in MTC; familial and sporadic
FT                                forms; dbSNP:rs377767405).
FT                                /FTId=VAR_009478.
FT   VARIANT     631    631       D -> G (in thyroid carcinoma; somatic
FT                                mutation; dbSNP:rs121913308).
FT                                /FTId=VAR_006321.
FT   VARIANT     632    634       ELC -> DVR (in MEN2A; dbSNP:rs377767408).
FT                                /FTId=VAR_006322.
FT   VARIANT     634    635       CR -> WG (in MEN2A).
FT                                /FTId=VAR_006329.
FT   VARIANT     634    634       C -> CHELC (in MEN2A).
FT                                {ECO:0000269|PubMed:9097963}.
FT                                /FTId=VAR_009479.
FT   VARIANT     634    634       C -> F (in MEN2A and pheochromocytoma;
FT                                dbSNP:rs75996173).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006324.
FT   VARIANT     634    634       C -> G (in MEN2A and pheochromocytoma;
FT                                dbSNP:rs75076352).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006323.
FT   VARIANT     634    634       C -> R (in MEN2A, pheochromocytoma and
FT                                MTC; familial form; also found as somatic
FT                                mutation in a sporadic thyroid carcinoma;
FT                                dbSNP:rs75076352).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7860065,
FT                                ECO:0000269|PubMed:8103403}.
FT                                /FTId=VAR_006326.
FT   VARIANT     634    634       C -> S (in MEN2A, pheochromocytoma and
FT                                MTC; familial form; dbSNP:rs75076352).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006327.
FT   VARIANT     634    634       C -> W (in MEN2A, pheochromocytoma and
FT                                MTC; familial form; dbSNP:rs77709286).
FT                                {ECO:0000269|PubMed:12000816}.
FT                                /FTId=VAR_006328.
FT   VARIANT     634    634       C -> Y (in MEN2A, pheochromocytoma and
FT                                MTC; familial form; dbSNP:rs75996173).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:7860065,
FT                                ECO:0000269|PubMed:7915165,
FT                                ECO:0000269|PubMed:8099202}.
FT                                /FTId=VAR_006325.
FT   VARIANT     636    636       T -> TCRT (in MEN2A).
FT                                {ECO:0000269|PubMed:9452064}.
FT                                /FTId=VAR_006330.
FT   VARIANT     639    639       A -> G (in MTC; sporadic form).
FT                                {ECO:0000269|PubMed:11692159}.
FT                                /FTId=VAR_012743.
FT   VARIANT     640    640       A -> G (in MEN2A; dbSNP:rs78935588).
FT                                {ECO:0000269|PubMed:10522989}.
FT                                /FTId=VAR_009480.
FT   VARIANT     641    641       A -> G (in MTC; sporadic form).
FT                                {ECO:0000269|PubMed:11692159}.
FT                                /FTId=VAR_012744.
FT   VARIANT     679    679       P -> L (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067117.
FT   VARIANT     690    690       S -> P (in HSCR1; sporadic form).
FT                                /FTId=VAR_006331.
FT   VARIANT     691    691       G -> S (in dbSNP:rs1799939).
FT                                {ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9223675,
FT                                ECO:0000269|PubMed:9497256}.
FT                                /FTId=VAR_006332.
FT   VARIANT     694    694       R -> Q (in HSCR1; dbSNP:rs141185224).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067118.
FT   VARIANT     749    749       R -> T (in dbSNP:rs34288963).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041765.
FT   VARIANT     762    762       E -> Q (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:7704557}.
FT                                /FTId=VAR_009481.
FT   VARIANT     765    765       S -> P (in HSCR1; dbSNP:rs75075748).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:8114938,
FT                                ECO:0000269|PubMed:9043870}.
FT                                /FTId=VAR_009493.
FT   VARIANT     767    767       S -> R (in HSCR1; sporadic form).
FT                                /FTId=VAR_006334.
FT   VARIANT     768    768       E -> D (in MTC; familial and sporadic
FT                                forms; dbSNP:rs78014899).
FT                                {ECO:0000269|PubMed:7784092,
FT                                ECO:0000269|PubMed:7845675,
FT                                ECO:0000269|PubMed:8807338}.
FT                                /FTId=VAR_006335.
FT   VARIANT     778    778       V -> I (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                constitutively phosphorylated;
FT                                dbSNP:rs75686697).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044395.
FT   VARIANT     783    783       N -> S (in HSCR1; dbSNP:rs587778656).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067119.
FT   VARIANT     790    790       L -> F (in MEN2A and MTC; familial form;
FT                                dbSNP:rs75030001).
FT                                {ECO:0000269|PubMed:9506724}.
FT                                /FTId=VAR_009482.
FT   VARIANT     791    791       Y -> F (in HSCR1, pheochromocytoma, MTC
FT                                and MEN2A; familial form;
FT                                dbSNP:rs77724903).
FT                                {ECO:0000269|PubMed:12000816,
FT                                ECO:0000269|PubMed:9090527,
FT                                ECO:0000269|PubMed:9506724}.
FT                                /FTId=VAR_009483.
FT   VARIANT     804    804       V -> L (in MTC; familial form;
FT                                dbSNP:rs79658334).
FT                                {ECO:0000269|PubMed:7784092}.
FT                                /FTId=VAR_006336.
FT   VARIANT     804    804       V -> M (in MTC; familial form;
FT                                dbSNP:rs79658334).
FT                                {ECO:0000269|PubMed:10826520,
FT                                ECO:0000269|PubMed:9452077}.
FT                                /FTId=VAR_006337.
FT   VARIANT     813    813       R -> Q (in HSCR1; sporadic form).
FT                                {ECO:0000269|PubMed:10090908}.
FT                                /FTId=VAR_009484.
FT   VARIANT     826    826       Y -> S (in dbSNP:rs34617196).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041766.
FT   VARIANT     830    830       G -> R (in HSCR1; dbSNP:rs200127630).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067120.
FT   VARIANT     844    844       R -> L (in MTC; familial form;
FT                                dbSNP:rs55947360).
FT                                {ECO:0000269|PubMed:10826520,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_011582.
FT   VARIANT     873    873       R -> Q (in HSCR1; sporadic form).
FT                                /FTId=VAR_006338.
FT   VARIANT     883    883       A -> F (in MEN2B; somatic mutation in
FT                                sporadic medullary thyroid carcinoma;
FT                                requires 2 nucleotide substitutions;
FT                                dbSNP:rs377767429).
FT                                {ECO:0000269|PubMed:9294615,
FT                                ECO:0000269|PubMed:9360560}.
FT                                /FTId=VAR_009485.
FT   VARIANT     891    891       S -> A (in MTC; familial form;
FT                                dbSNP:rs75234356).
FT                                {ECO:0000269|PubMed:9398735}.
FT                                /FTId=VAR_009486.
FT   VARIANT     893    893       F -> L (in HSCR1; sporadic form).
FT                                /FTId=VAR_006339.
FT   VARIANT     894    894       G -> S (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                constitutively phosphorylated; expressed
FT                                only the immature intracellular form).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044396.
FT   VARIANT     897    897       R -> Q (in HSCR1; sporadic form;
FT                                dbSNP:rs76087194).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:8114938}.
FT                                /FTId=VAR_006340.
FT   VARIANT     907    907       K -> E (in HSCR1; sporadic form;
FT                                dbSNP:rs377767430).
FT                                /FTId=VAR_006341.
FT   VARIANT     907    907       K -> T (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067121.
FT   VARIANT     918    918       M -> T (in MEN2B and MTC; sporadic form;
FT                                somatic mutation; also found in a patient
FT                                with renal agenesis; dbSNP:rs74799832).
FT                                {ECO:0000269|PubMed:18252215,
FT                                ECO:0000269|PubMed:7906417,
FT                                ECO:0000269|PubMed:7906866,
FT                                ECO:0000269|PubMed:7911697,
FT                                ECO:0000269|PubMed:8595427,
FT                                ECO:0000269|PubMed:8807338}.
FT                                /FTId=VAR_006342.
FT   VARIANT     921    921       E -> K (in HSCR1; sporadic form).
FT                                /FTId=VAR_006343.
FT   VARIANT     922    922       S -> F (in MTC; sporadic form;
FT                                dbSNP:rs377767432).
FT                                {ECO:0000269|PubMed:11692159}.
FT                                /FTId=VAR_012745.
FT   VARIANT     922    922       S -> Y (rare polymorphism;
FT                                dbSNP:rs377767432).
FT                                {ECO:0000269|PubMed:8595427}.
FT                                /FTId=VAR_009487.
FT   VARIANT     946    946       T -> M (in MEN2B and MTC; familial form).
FT                                /FTId=VAR_006345.
FT   VARIANT     961    961       F -> L (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067122.
FT   VARIANT     972    972       R -> G (in HSCR1; familial form;
FT                                dbSNP:rs76534745).
FT                                {ECO:0000269|PubMed:7704557,
FT                                ECO:0000269|PubMed:8114938}.
FT                                /FTId=VAR_006346.
FT   VARIANT     973    973       P -> L (in HSCR1; familial form).
FT                                {ECO:0000269|PubMed:7704557}.
FT                                /FTId=VAR_006347.
FT   VARIANT     980    980       M -> T (in HSCR1; sporadic form).
FT                                /FTId=VAR_006348.
FT   VARIANT     982    982       R -> C (in dbSNP:rs17158558).
FT                                {ECO:0000269|PubMed:14566559,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:7633441,
FT                                ECO:0000269|PubMed:9760196}.
FT                                /FTId=VAR_006349.
FT   VARIANT    1039   1039       P -> L (in CCHS; with colonic
FT                                aganglionosis; dbSNP:rs79853121).
FT                                {ECO:0000269|PubMed:9497256}.
FT                                /FTId=VAR_018157.
FT   VARIANT    1039   1039       P -> Q (in dbSNP:rs79853121).
FT                                /FTId=VAR_009488.
FT   VARIANT    1049   1049       P -> L (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF). {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044397.
FT   VARIANT    1052   1052       L -> V (in HSCR1).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067123.
FT   VARIANT    1059   1059       Missing (in HSCR1).
FT                                {ECO:0000269|PubMed:10484767,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009489.
FT   VARIANT    1061   1061       L -> P (in HSCR1; dbSNP:rs536486113).
FT                                {ECO:0000269|PubMed:10484767,
FT                                ECO:0000269|Ref.56}.
FT                                /FTId=VAR_009490.
FT   VARIANT    1062   1062       Y -> C (in HSCR1; dbSNP:rs587778659).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_067124.
FT   VARIANT    1064   1064       M -> T (in HSCR1; familial form;
FT                                dbSNP:rs149513065).
FT                                {ECO:0000269|PubMed:22174939}.
FT                                /FTId=VAR_009491.
FT   VARIANT    1067   1067       P -> S (in a patient with renal agenesis;
FT                                unknown pathological significance;
FT                                prevents phosphorylation in response to
FT                                GDNF; dbSNP:rs775583354).
FT                                {ECO:0000269|PubMed:18252215}.
FT                                /FTId=VAR_044398.
FT   VARIANT    1112   1112       F -> Y (in a bladder transitional cell
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041767.
FT   MUTAGEN     707    707       D->N: Impaired cleavage by caspase-3 and
FT                                loss of induced cell death.
FT                                {ECO:0000269|PubMed:21357690}.
FT   MUTAGEN     708   1114       Missing: Loss of induced cell death, but
FT                                increased cell aggregation.
FT                                {ECO:0000269|PubMed:21357690}.
FT   MUTAGEN     758    758       K->R: Loss of kinase activity. No effect
FT                                on interaction with and dissociation from
FT                                CBLC and CD2AP.
FT                                {ECO:0000269|PubMed:18753381,
FT                                ECO:0000269|PubMed:21357690}.
FT   CONFLICT    647    647       I -> V (in Ref. 6; AAA36786).
FT                                {ECO:0000305}.
FT   CONFLICT    664    664       A -> S (in Ref. 1; BAF84496).
FT                                {ECO:0000305}.
FT   CONFLICT    750    750       A -> G (in Ref. 9; AAA36524).
FT                                {ECO:0000305}.
FT   CONFLICT    904    904       S -> P (in Ref. 6; AAA36786).
FT                                {ECO:0000305}.
FT   STRAND       30     32       {ECO:0000244|PDB:2X2U}.
FT   STRAND       34     41       {ECO:0000244|PDB:2X2U}.
FT   STRAND       49     52       {ECO:0000244|PDB:2X2U}.
FT   STRAND       70     73       {ECO:0000244|PDB:2X2U}.
FT   HELIX        75     77       {ECO:0000244|PDB:2X2U}.
FT   STRAND       79     82       {ECO:0000244|PDB:2X2U}.
FT   STRAND       85     88       {ECO:0000244|PDB:2X2U}.
FT   TURN         90     92       {ECO:0000244|PDB:2X2U}.
FT   STRAND       94     99       {ECO:0000244|PDB:2X2U}.
FT   HELIX       103    111       {ECO:0000244|PDB:2X2U}.
FT   STRAND      120    126       {ECO:0000244|PDB:2X2U}.
FT   TURN        139    141       {ECO:0000244|PDB:2X2U}.
FT   STRAND      142    152       {ECO:0000244|PDB:2X2U}.
FT   HELIX       157    159       {ECO:0000244|PDB:2X2U}.
FT   HELIX       162    166       {ECO:0000244|PDB:2X2U}.
FT   STRAND      174    178       {ECO:0000244|PDB:2X2U}.
FT   STRAND      184    187       {ECO:0000244|PDB:2X2U}.
FT   HELIX       191    196       {ECO:0000244|PDB:2X2U}.
FT   STRAND      202    208       {ECO:0000244|PDB:2X2U}.
FT   STRAND      212    215       {ECO:0000244|PDB:2X2U}.
FT   STRAND      222    227       {ECO:0000244|PDB:2X2U}.
FT   TURN        231    233       {ECO:0000244|PDB:2X2U}.
FT   STRAND      235    245       {ECO:0000244|PDB:2X2U}.
FT   STRAND      252    263       {ECO:0000244|PDB:2X2U}.
FT   HELIX       705    711       {ECO:0000244|PDB:4CKJ}.
FT   TURN        715    717       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       721    723       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      724    732       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      734    744       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       746    748       {ECO:0000244|PDB:2IVS}.
FT   STRAND      750    760       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       766    779       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      790    794       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      796    798       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      801    805       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       812    817       {ECO:0000244|PDB:4CKJ}.
FT   TURN        819    821       {ECO:0000244|PDB:2IVS}.
FT   STRAND      844    846       {ECO:0000244|PDB:4CKI}.
FT   HELIX       848    867       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       877    879       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      880    883       {ECO:0000244|PDB:4CKJ}.
FT   TURN        884    886       {ECO:0000244|PDB:4CKJ}.
FT   STRAND      887    890       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       893    895       {ECO:0000244|PDB:2IVV}.
FT   TURN        900    902       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       915    917       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       920    925       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       930    945       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       957    959       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       960    965       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       978    987       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       992    994       {ECO:0000244|PDB:4CKJ}.
FT   HELIX       998   1012       {ECO:0000244|PDB:4CKJ}.
SQ   SEQUENCE   1114 AA;  124319 MW;  A3DA0CE01A19A441 CRC64;
     MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP
     EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT
     VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR
     PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV
     AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD
     ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR
     NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA
     QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE
     LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR
     CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR
     GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY
     HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP
     RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK
     QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH
     PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY
     EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL
     FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA
     STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA
     DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS
//
